Experts from the CVS Health Research Institute, writing today in the Journal of the American Medical Association, are calling for a reconsideration of treatment guidelines for high cholesterol as PCSK9 inhibitors hit the market.
The Food and Drug administration announced Friday that it had approved Praluent (alirocumab), a cholesterol-lowering PCSK9 inhibitor injection.
CVS Health weighs in on the next chapter in the debate about the impact of expensive drugs on the healthcare system in a commentary that appears today on the Health Affairs blog.
New cardiovascular health guidelines released this week could dampen the potential popularity of an up-and-coming class of cholesterol drugs, according to published reports.
Bristol-Myers Squibb has paid Isis Pharmaceuticals a $6 million milestone payment for regulatory approval to...